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Chapter I: Introduction

A. Background
The goal of evidence based dentistry, which can be applied to the specialized field of orthodontics,
is to allow the clinician to deliver the most effective, efficient, and predictable treatment [1].
Evidence based dentistry includes three fundamental components, two of which are in the hands
of the orthodontist: scientific evidence and clinical expertise [2]. The final component incorporates
the patients’ needs and preferences; patient preferences regarding orthodontic treatment often
hinge around the treatment duration [3]. According to the most recently published systematic
review, comprehensive orthodontic treatment, on average, requires less than two years to complete
[4]. However, in some cases, treatment time is increased from this two year average duration.
Factors, such as extraction therapy, earlier initiation of treatment for specific malocclusions, noncompliance, initial severity of the malocclusion, and impacted canines appear to be associated with
increased treatment time [5].

Increased orthodontic treatment time can result in a multitude of damaging effects to the oral cavity
such as: white spot lesions [6] [7], dental caries [7], root resorption [8], and gingival inflammation
[9]. Increased time in orthodontic appliances can also lead to the decline of patients’ compliance
[4], which can impact the quality of the orthodontic finish. Therefore, the ability to decrease
treatment time would be advantageous to both patients and orthodontists alike. In a recent
publication from Uribe et al., it was found that about 85% of adult patients and 95% of adolescent
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patients wished that orthodontic treatment lasted 18 months or less [3]; this would be a 25%
reduction in the overall treatment duration than the most currently reported average [5].

There exist many modalities to accelerate the rate of tooth movement, which has spawned the
development of a variety of products marketed by the orthodontic industry and advertised to
decrease treatment time. However, about half of the marketed orthodontic products are
investigated after their introduction, with many of the analyses not confirming the purported
effectiveness of the intervention [10]. Historically, attempts to find a modality to enhance the rate
of tooth movement, in order to decrease overall time in orthodontic appliances, have focused on
three main approaches: 1. Pharmacological, 2. Surgical, and 3. Mechanical.

Published investigations have previously examined the effects of local or systemic
pharmacological administration of factors such as parathyroid hormone (PTH) [11], vitamin D3
[12], prostaglandins [13], and thyroxin [14]. While these biological factors have been found to
increase the rate of tooth movement, they have also shown adverse effects, such as root resorption
[15] [16], drug-induced side effects, for those agents delivered systemically [17], or pain when
injected locally [18].

Surgical procedures such as corticotomy [19] [20] [21], corticision [22] , and piezocision [23] have
also been cited as techniques to increase the rate of orthodontic tooth movement. Some proponents
of these surgical techniques suggest that this increased rate of tooth movement is due the Regional
Acceleratory Phenomenon (RAP), first proposed by bone biologist Harold Frost as an increase in
2

bone turnover and decrease in bone density after injury [19] [24]. However, a multitude of studies
have shown the short-term, 2-3-month average effect of the RAP, which decreases the significance
of its utilization [19]. In addition, due to the invasive nature of the surgical methods, patients are
less inclined to consent to these adjunctive treatments [3] [25].

Lastly, the use of mechanical vibration to the dentition has also been hypothesized to increase the
rate of tooth movement by stimulating bone remodeling through exogenous piezoelectricity [26].
The use of adjunctive vibration therapy could be well-accepted by patients due to its non-invasive
nature without any adverse systemic effects. In fact, Uribe et al. found that adult patients,
adolescent patients, and their parents were 78%, 87%, and 70% neutral or willing to use a vibrating
device, respectively [3]. However, although these intraoral vibrating devices already exist on the
market and are utilized in many practices by many patients, it is still unknown if they do, in fact,
decrease overall treatment time.

1. Vibration and Orthodontic Tooth Movement
The use of an external vibrational force as a supplemental appliance in combination with
orthodontic treatment was first proposed in a 1982 patent by Craven Kurz in which he described a
vibrating headgear/mouthpiece device [27]. Animal studies examining the effect of vibration have
exhibited the potential for an acceleration of tooth movement by triggering the inflammatory
process through alteration of the periodontal apparatus or by increasing levels of pro-inflammatory
cytokines, such as Receptor Activator of Nuclear Factor Kappa-B Ligand (RANK), an osteoclast
activator [28] [29] [30]. On the other hand, studies have demonstrated that the application of
3

mechanical vibration with low-magnitude and high frequency can enhance bone remodeling,
prevent bone loss, and improve bone healing in animals and humans [31] [32] [33] [34]. However,
contrary to the possible mechanisms underlying the acceleratory effects, the process by which
these appositional effects occur, is not clearly understood.

Following three landmark papers by Mao et al., which showed the potential for vibrational forces
to increase cranial suture width and bone formation [35] [36] [37], a venture to deliver vibrational
therapy to humans was achieved; a novel device, called AcceledentÒ, which applies a cyclic force
of 25g at a frequency of 30 Hz was developed in 2009. However, the AcceledentÒ device is a prime
example of the objective behind the meta-epidemiological investigation by Seehra et al. [10]: this
device was marketed and adopted by the orthodontic community before its clinical use was
verified. In a case report which included 14 patients who used the novel AcceledentÒ device, Kau
et al. reported a monthly rate of tooth movement of 2.1mm and 3.0mm in the mandibular and the
maxillary arches, respectively. Although there were no control patients used for comparison, Kau
et al. concluded that this rate of tooth movement was significantly faster than the usual 1 mm of
tooth movement per month previously reported in the literature [38]. A randomized clinical trial
was then performed by Pavlin et al., assessing the rate of space closure during canine retraction
with supplemental vibration provided by the AcceledentÒ device. The results showed an average
rate of tooth movement of 1.16 mm/month when the AcceledentÒ appliance was used for 20
minutes/day, corresponding to an increase of 48% in the rate of space closure [39]. Another
randomized clinical trial was performed by Miles et al., using a slightly different vibration device
called the Tooth Masseuse. It delivers a vibrational force of higher frequency, but lower amplitude
4

than the AcceledentÒ device. They investigated the effect of vibration on lower incisor alignment
as measured by the Little’s Irregularity Index, and concluded that there was no statistically
significant difference between the rate of tooth movement between the control and experimental
groups [40]. Using a similar protocol, Bowman et al. found an increased rate of leveling and
aligning during comprehensive treatment by 30% and 29-40%, respectively; however, this
research was retrospective in nature, leading to some inherent bias [41].

A systematic review was published in the Cochrane Library in 2015, which included two of the
aforementioned studies: Miles et al. (2014) and Pavlin et al. (2015). The Cochrane Review
concluded that all of the available evidence was of very low quality. Therefore, it was not possible
to determine if there is a positive effect of using a vibration device in conjunction with fixed
appliances to accelerate tooth movement [42].

Since the systematic review in 2015, several high-quality prospective, randomized clinical trials
have been published. Woodhouse et al. conducted a prospective randomized clinical trial which
found no evidence that supplemental vibration added to regular orthodontic treatment increases
the rate of initial alignment or reduces the amount of time required to achieve final alignment [43].
Miles et al. published two randomized clinical trials comparing the effects of the AcceledentÒ
device on the rate of tooth movement with lower incisor irregularity and space closure during
canine retraction, in 2016 and 2018, respectively. Neither paper found an effect of vibration on the
rate of incisor alignment [44] or the rate of space closure [45]. Furthermore, in the 2018
publication, Miles compared the rate of canine retraction between subjects who were termed good
5

compliers (daily usage of the AcceledentÒ device > 75%) versus control subjects; the effect of
vibration on the rate of space closure was still not significant [45]. Lastly, a multi-center, 3-arm
parallel randomized clinical trial undertaken by DiBiase and colleagues in England was published
recently. They assessed the effect of AcceledentÒ on the rate of mandibular space closure (canine
retraction) and overall treatment duration; however, they did not find any significant differences
between the subjects in the control group and the subjects in the AcceledentÒ group [46]. While
the most recent, well-conducted research suggests that there is no advantage to the application of
cyclical forces on the rate of tooth movement [43] [44] [45] [46], there is still a need for additional
well-designed clinical trials.

2. Vibration Treatment- Pain and Quality of Life During Orthodontic Treatment
In addition to the advertised enhanced effects on the rate of tooth movement, the AcceledentÒ
device has been marketed as an adjunctive method to reduce the amount of dental pain that
orthodontic patients experience during active treatment. Four randomized clinical trials with
contradictory results have been published regarding this effect: one study concluded that pain was
decreased when a vibration appliance was used [47], while the other three studies found no
statistically significant differences between patients using a vibration device and a control group
[40] [44] [48]. The study by Woodhouse et al. included a novel sham device group into the study
design. However, even with the sham device group, which might uncover a placebo effect, there
was no significant differences found in pain levels during the week following the placement of
fixed appliances and wire insertion between the three groups [48]. Lastly, in the randomized
clinical trial conducted by Miles et al. in 2016, pain levels at different timepoints were measured
6

using the Visual Analog Scale. They found no significant differences in reported pain levels at any
timepoint between subjects using the AcceledentÒ device and control subjects [44].

According to published research, the presence of a malocclusion is associated with a low Oral
Health Quality of Life (OHQoL) [49]. Irrespective of this information, the literature does not
support any conclusive evidence on the psychosocial effect of orthodontic treatment. In studies
performed on Brazilian populations, both adult and adolescent patients who received orthodontic
treatment were found to have a significantly higher OHQoL after treatment is completed than
untreated subjects [49] [50]. However, follow-up research has shown that some patients go through
a transitional phase of deterioration of the OHQoL during the active orthodontic phase, possibly
due to pain, gingivitis, ulceration, and speech problems [51] [52]. Due to a dearth of literature
investigating the effects of orthodontic treatment on OHQoL, future research should be undertaken
to assess not only the psychosocial impact, but also other factors that could possibly contribute to
the improvement of the overall orthodontic experience.

3. Vibration Treatment- Bone Remodeling Biomarker Measurements
Orthodontic tooth movement occurs subsequent to the initiation of the inflammatory process by
remodeling of the periodontal ligament (PDL) and alveolar bone [53]. While vibrational loading
has been claimed to stimulate bone remodeling [26], and thus tooth movement, the underlying
biological mechanisms are not clearly understood. An important marker to illustrate the rate of
bone turnover is Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), a molecular
biomarker secreted by the osteoblasts. RANKL is responsible for the recruitment, differentiation,
7

and survival of osteoclasts. The binding of RANKL with RANK (which is expressed at the surface
of the osteoclast) induces the differentiation of the immature osteoclasts into functional cells which
can resorb bone. On the other hand, osteoprotegerin (OPG), also produced by the osteoblasts, acts
as a soluble receptor for RANKL. This inhibits the final stages of the osteoclast differentiation,
thereby serving as a negative feedback system for the maintenance of equally balanced bone
formation and resorption [53]. The role of the OPG/RANKL system in bone remodeling has been
illustrated in several studies performed on animals [54] [55] [56] and recently on humans during
orthodontic treatment [57] [58].

Matrix metalloproteinases (MMPs), a family of endopeptidases that play a key role in collagen
breakdown, tissue remodeling and degradation of the extracellular matrix, serve as important
biomarkers of bone remodeling in conjunction with orthodontic tooth movement [53]. Multiple
studies have shown increased expression of certain metalloproteinases during orthodontic
treatment: increased levels of MMP-9 were found in the gingival crevicular fluid in response to
external pressure on teeth [59] [60] [61] [62] [63]. MMP-13 was also expressed in the PDL and
alveolar bone soon after the application of an orthodontic force [62] [64] [65]. Increased levels of
MMP-3 and MMP-8 have also been found after orthodontic tooth movement in both animal and
human models [62] [65] [66] [67].

Lastly, Tumor Necrosis Factor alpha (TNF-α) and interleukins are cytokines which increase with
orthodontic force application in rats [68] and humans [59] [69] and are involved in the induction
of osteoclastogenesis. Important interleukins such as IL-1 [60] [69] [70], IL-6 [71] [67], IL-8 [72]
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and IL-17 [73] are specific regulators in the bone remodeling process and therefore, are present in
higher concentrations during orthodontic tooth movement.

To date, there is only one clinical study measuring the effect of vibration on bone metabolism
biomarkers (IL-1β) during orthodontic tooth movement. Leethanakul et al. published their findings
in 2016. They employed a split-mouth study design and a small sample-size of 15 subjects. The
vibratory stimulus was provided by an electric Colgate Multi-Action toothbrush, rather than the
AcceledentÒ device. Subjects were asked to apply the electric toothbrush for 5 minutes, 3x/day to
one of their canine teeth being retracted for the duration of the 3-month study. Levels of IL-1β
were measured in the gingival crevicular fluid (GCF) at four timepoints, 2 weeks apart. They found
that after 2 months, the levels of IL-1β were higher on the pressure sides of the experimental
canines, which was associated with an increased rate of tooth movement [74]. However, while
these results are interesting, they should be interpreted with caution; due to the nature of the
toothbrush as the vibratory agent, the force cannot be calibrated between patients. In addition, the
sample size was small.

Similar to the conclusions of Leethanakul et al., the expression of various pro-inflammatory
biomarkers of bone remodeling in subjects utilizing vibration in conjunction with orthodontic
treatment could elucidate the specific pathways that are activated when tooth movement
acceleration occurs. The test chosen to conduct this assessment must have an acute sensitivity to
the factors of interest, as well as be minimally invasive to allow for good acceptance from patients.
Multiple methods to assess biological factors have been published in the literature including:
blood, gingival crevicular fluid, and saliva. Recently, there has been an increased use of salivary
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analysis in the oral health field. It has been proposed that saliva mirrors the body’s overall health,
a statement which qualifies its prospective use as diagnostic tool. Saliva has many advantages such
as its non-invasive nature, its ease of use, and the fact that sufficient quantities can be easily
obtained for analysis [75]. Saliva has previously been used to predict the risk of caries and
periodontitis, as well as the diagnosis of oral cancer, breast cancer, salivary gland disease, hepatitis,
HIV and HCV [76]. Within the field of dentistry, only a few studies have used saliva to evaluate
the expression of bone remodeling factors [77] [78]; however, this emerging field shows great
promise for future diagnostics.

B. Study Rationale
Orthodontic treatment duration averages around 24 months [4] . There are several advantages for
reduced treatment time: decreased risk of root resorption [8] and decalcification [6] [7], less time
for maintenance of periodontal health [9], and a decreased chance of patient non-compliance from
prolonged treatment [4], which can impact orthodontic outcomes. AcceledentÒ advertises the
proposed benefits of decreased treatment time and decreased pain when using their device, and we
aim to investigate if these claims are supported by a high-quality investigation.

Clinical studies which investigate the use of a vibration device in conjunction with fixed appliances
have assessed the acceleration of tooth movement, either during the alignment or space closure
phase, and the amount of experienced pain. These studies have produced a range of conclusions,
which has sourced the controversy within this field of tooth movement acceleration [39] [40] [43]
[44] [45] [46] and within the domain of pain [40] [48] [47]. Furthermore, although the systematic
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review published in the Cochrane Journal does not include the four most recent randomized
clinical trials, it stipulated a very low level of evidence among the included articles [42]. Therefore,
there is a clear need for more well-designed controlled studies in order to elucidate the clinical
effects of the application of vibration on orthodontic tooth movement.

Lastly, the biological mechanism underlying the acceleration of the rate of tooth movement is
unknown. The identification of specific biomarkers in the saliva that are stimulated by
supplemental vibration could help our orthodontic profession to understand the pathways involved
in accelerated bone remodeling. In the future, this could lead to treatment which would target
specific acceleratory biomarkers with the objective to reduce orthodontic treatment time. The aim
of this study is to identify novel biological factors which are expressed in subjects undergoing
orthodontic tooth movement in conjunction with vibration provided by the AcceledentÒ device.

C. Outcome Assessment
Primary outcomes: Changes in the expression of salivary biomarkers of bone remodeling
Secondary outcomes:
o Changes in the rate of alignment of lower anterior teeth (canine to canine)
o Changes in tooth mobility
o Changes in pain and Oral Health and Quality of Life
o Average compliance use of a vibration device
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Chapter II: Hypotheses, Objectives, and Aims

A. Hypotheses and General Objectives
1. Null Hypotheses
1. There is no difference in the expression of biological markers of bone remodeling between
combined vibration-fixed appliance treatment and fixed appliance treatment alone.

2. There is no difference in the degree of tooth mobility in patients undergoing combined
vibration-fixed appliance treatment compared to fixed appliance treatment alone.

3. There is no difference in the rate of lower incisor alignment in patients undergoing combined
vibration-fixed appliance treatment compared to fixed appliance treatment alone during the first
3 months of treatment.

4. There is no difference in the reported pain or reported oral health quality of life in patients
undergoing combined vibration-fixed appliance treatment and fixed appliance treatment alone.

2. General Objectives
There is a clear lack of evidence in the orthodontic literature about the effects of a vibration device
on the rate of tooth movement, pain, and oral health quality of life. Additionally, the biological
mechanism by which vibration may increase the rate of tooth movement is still unknown. The
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primary objective of this study is to assess the potential influences of a vibration device on the
expression of biomarkers of bone remodeling.

B. Specific Aims and Objectives
1. To determine if supplemental vibration in addition to fixed orthodontic appliance treatment can
alter the expression of biological factors involved in bone remodeling during orthodontic tooth
movement.

2. To further elucidate the role of supplemental vibration on the degree of tooth mobility during
fixed orthodontic appliance treatment.

3. To determine if supplemental vibration in addition to fixed orthodontic appliance treatment
increases the rate of orthodontic tooth movement during the alignment phase of treatment.

4. To evaluate the effect of supplemental vibration on experienced pain and on the oral health
quality of life in subjects undergoing orthodontic treatment.

Chapter III: Materials and Methods

A. Study Design and Screening Procedures
1. Study Design
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This study was approved by the Institutional Review Board (IRB) of University of Connecticut
(IRB #14-117-2). The aim of this study was to perform a randomized clinical trial recruiting a total
of 40 patients randomly divided in four groups: (1) 10 male subjects randomized to the control
group; (2) 10 male subjects randomized to the vibration group; (3) 10 female subjects randomized
to the control group; (4) 10 male subjects randomized to the vibration group. The randomization
of subjects is diagrammed in the chart below:

Experimental Group (N=10)
AcceledentÒ device + Fixed
appliance

Male Subjects
(N=20)
Control Group (N=10)
Fixed appliance only

Orthodontic Patients
(N=40)
(who meet inclusion criteria
and consent to participation)

Experimental Group (N=10)
AcceledentÒ device + Fixed
appliance

Female Subjects
(N=20)
Control Group (N=10)
Fixed appliance only

No randomized clinical trials are currently available to predict the effects of vibration with the
AcceledentÒ device on the expression of pro-inflammatory biomarkers. Therefore, this study
serves as a pilot study consisting of 40 subjects randomized into 4 groups divided by gender and
vibration or no-vibration treatment.
14

2. Screening & Recruitment Procedures
Prospective subjects were screened for potential inclusion in this study during the regular screening
procedures followed for all new patients who present to the orthodontic clinic at UCONN Health.
The orthodontic provider assigned to the patient at the screening appointment determined if the
patient was likely to qualify according to the inclusion/exclusion criteria for participation in the
trial and advised the study coordinators (MCC/SR) if the clinical indicators were met. The initial
eligibility requirements included any healthy male or female patient between the age of 15-35
years old, non-smoker, not prescribed any medications, with good oral hygiene, a minimum of
5mm of lower anterior crowding (canine to canine), and a non-extraction treatment plan. If the
prospective subjects met the initial criteria, the study coordinator then confirmed the possible
eligibility by consulting the screening forms, models, and/or radiographs. In the situation where
the patient was between the age of 15.0-17.11 years old, the patient’s provider asked the patient’s
parent for permission to provide the clinical information to the study coordinator.

3. Enrollment
After the patient’s primary provider determined their patient’s potential inclusion into the trial and
verified that their patient was interested in becoming a subject, the study coordinator met with the
patient at their next appointment. The study was then explained to the patient in detail and informed
consent was obtained by the patient him/herself and/or the patient’s parent (in the situation where
the subject was under 18 years old). Potential subjects had to satisfy the following
inclusion/exclusion criteria in order to be enrolled in the study:
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Inclusion Criteria
Healthy, non-smoker with no systemic medical
conditions and taking no routine medications
15 to 35 years of age at the time of bonding (T0)
Non-extraction treatment plan or no extractions
required during the first 6 months of treatment
At least 5mm of crowding in the mandibular arch
st
st
Full-complement dentition: 1 molar to 1 molar
Good oral hygiene

Exclusion Criteria
Patients requiring extractions as part of their treatment plan
Smoking or excessive alcohol consumption
Patients with edentulous areas (missing teeth)
Evidence of periodontal disease (any pocket depths >4mm)
Use of anti-inflammatory drugs within 2 days of bonding
Uncontrolled diabetes
Dentofacial deformities (cleft palate, hemifacial microsomia,
etc.)
Subjects routinely taking any of the following medications:
+ Corticosteroids (including for asthma)
+ Bisphosphonates
+ Anti-inflammatory drugs such as Ibuprofen
+ Nicotine Patch
+ Estrogen
+ Opioids
+ Growth Hormone
+ Relaxin
+ Anti-coagulants
+ Stimulants (ADHD)
Diseases that could affect bone metabolism:
+ Parathyroid or thyroid dysfunction
+ Osteoporosis or Osteomalacia
+ Vitamin D deficiency
+ Fibrous dysplasia
+ Paget’s disease
+ Multiple Myeloma
+ Osteogenesis Imperfecta
+ History of Bone Metastasis

B. Study Procedures
1. Standardized Orthodontic Treatment Protocol
The patients enrolled in this clinical trial had to follow a standardized protocol in order to minimize
any potential variability in treatment that could confound the trial outcomes. All subjects were
bonded with passive self-ligating brackets (CarriereÒ) featuring a 0.022” x 0.025” slot and MBT
prescription from lower right second premolar to lower left second premolar, as well as a bonded
tube on the first molars. At the bonding appointment (T0), a 0.014” Cu-NiTi wire was engaged
into the mandibular arch brackets and was maintained through the T2 appointment. Before the
0.014” Cu-NiTi wire was retied at the T2 appointment, it was removed from the subject’s mouth
16

to verify that there was no permanent deformation that could confound the potential for lower
incisor alignment. At T2, the lower archwire was switched to a 0.014” x 0.025” Cu-NiTi wire.
After initial bonding (T0), all subjects returned for trial timepoints T1, T2, T3 in conjunction with
their regular orthodontic adjustments with their orthodontic provider every 4-6 weeks.

If a bracket debonded between adjustment appointments, the subject had 7 days to advise his/her
provider and report to the clinic to have the bracket rebonded again to the ideal position. In
addition, the subjects were instructed not to take any anti-inflammatory medications during the
course of the trial and to abstain from eating or drinking for one hour prior to their next four
appointments (T0, T1, T2, T3 timepoints). Failure to follow this protocol led to immediate
disqualification from the study.

2. Randomization Procedure
Block randomization was utilized for randomization of subjects included in this trial. Since trial
groups were subdivided by gender, separate randomization into the AcceledentÒ or control group
was performed separately for male and female subjects. 40 opaque envelops with allocation group
assignments inside (10 AcceledentÒ / 10 control) were assembled for each group (20 male and 20
female subjects). During the bonding appointment (T0), the subject was asked to pick an envelope
and disclose their allocated group. For trial subjects randomized into the AcceledentÒ group,
instructions on how to operate the AcceledentÒ device were specified by the study coordinator
(MMC/SR). Subjects were instructed to use the AcceledentÒ device for 20 minutes per day
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throughout the entirety of the study duration (approximately 3 months) according the to
manufacturer’s instructions, which were included with the device.

3. Data Collection Procedure
At the bonding appointment (T0), baseline measurements of the following data were recorded
and/or collected: (1) unstimulated whole saliva, (2) Periotest measurements, (3) an alginate
impression of the mandibular arch, and (4) Oral Health Quality of Life questionnaire. The
aforementioned four measurements were collected/recorded again at the T1 timepoint (5-6 weeks
later), T2 timepoint (10-12 weeks later), and T3 timepoint (15-18 weeks later). Each subject was
scheduled at approximately the same time of the day in order to minimize any differences in
salivary biomarker levels due to circadian rhythms. In addition, subjects were given a Pain Diary
to fill out for the first 7 days following their T0, T1, and T2 appointments. Subjects were instructed
to return the Pain Diary at the following appointment.

o Saliva Collection and Analysis
Collection of unstimulated whole saliva was performed following the protocol described by
Navazesh and Kumar [79]. The saliva was collected into a sterile tube at T0, T1, T2, and T3 by
passive drooling for either 15 minutes or until 10 mL was reached. Protease inhibitor was then
added to the saliva in a ratio of 150ul protease inhibitor/10mL saliva and then centrifuged at 4000
rpm for 30 minutes at 4º Celsius, in order to remove cellular debris. Throughout the saliva
collection and processing, the sample was kept on ice to ensure preservation of the protein
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biomarkers. The samples were stored in a -80º Celsius freezer until biomarker analysis was
ultimately performed.

Salivary biomarkers were assessed with Multiplex assay. Seventeen biomarkers were analyzed
with the Multiplex analysis: OPN (osteopontin), RANKL, SOST (sclerostin), OPG, MMP1,
MMP8, MMP9, MMP13, TNF-α, IL-1β, IL-3, IL-6, IL-8, IL-11, IL-18, and DKK1. Protein assay
of all saliva samples was completed and the samples were diluted to equal protein concentrations
before Multiplex assay was initiated. Multiplex panels were supplied by R&D Systems, Inc and
were ran by the Core Laboratory at UCONN Health.

o Cast Analysis
Dental casts were assessed by one blinded evaluator (DFL) to determine the rate of tooth
movement. Each mandibular model was evaluated for the mandibular anterior alignment from
canine to canine, using Little’s Irregularity Index. This index uses the displacement of the adjacent
anatomic contact points of the mandibular incisors (from the mesial of the right canine to the mesial
of the left canine) in millimeters and determines the total Irregularity Index of the subject by adding
the five measurements together [80]. The measurements were recorded for all 40 subjects at all
four study timepoints: T0, T1, T2 and T3 with a digital caliper (Neiko Tools USA) held parallel to
the occlusal plane. The blinded evaluator recorded two Irregularity Index measurements for each
cast, taken one week apart and these two recorded measurements were averaged to produce the
Little’s Irregularity Index value per subject. Figure 1 illustrates how Little’s Irregularity Index is
measured on a cast [81].
19

o Periotest Measurements
The mobility of specific teeth in the mandibular arch (central incisors, canines, and second
premolars) was assessed with the Periotest (Siemens AG, Bensheim, Germany) device as
previously described by Liou et al. [82]. The lower wire was removed and the tip of the device
was held parallel to the floor, perpendicular to the tooth axis, and 2 mm away from the labial
surface. Before taking Periotest measurements, the study coordinator located an area on the labial
surface of the tooth which had sufficient space for the tip of the Periotest to contact the surface in
order to obtain consistent measurements. Each tooth was measured 3 times and the average
measurement was then calculated. The value obtained by the Periotest can range from -8.0 to +50.0
and the unit of measure is Periotest Value or PTV [83]. The scale correlates with Miller’s Index as
shown in Table 1.

o Orthodontic Pain Assessment
Subjects were instructed to record their subjective pain on a Pain Diary for the first seven days
including and following their T0, T1, and T2 appointments. Experienced pain was assessed using
the Visual Analog Scale (VAS). Subjects were asked to place a tick mark on the 10mm line
correlating with their experienced pain ranging from 0 (no pain) to 10 (extreme pain). The
completed diary was returned at the next appointment. The VAS for each subject at each trial
timepoint was recorded by measuring the location of the tick mark on the 10mm line and
converting this into an equivalent Visual Analog Score (1mm: VAS = 10). The Pain Diary supplied
to subjects to fill out and return can be found in Figure 2.
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o Oral Health Quality of Life (OHQoL)
Subjects were asked to complete an Oral Health Impact Profile (OHIP-14) questionnaire at their
T0, T1, T2, and T3 appointments in order to measure their perception of the impact of their oral
conditions, as well as the possible impact of using a vibration device on their well-being. The
questionnaire includes 14 questions divided into specific categories including functional
limitation, physical pain, psychological discomfort, physical disability, social disability, and
handicap. Each question is answered based on a 5-point scale correlated with frequency, with
scores that range from 0 (never) to 4 (very often). The recorded score (0-4) is then multiplied by
the attributed weight. The 14 values (score x weight) are summed together to produce a total
OHQoL value [84]. The OHQoL table with dimensions, questions, and their weights can be found
in Table 2.

o AcceledentÒ Device Usage Compliance
Average daily usage of the AcceledentÒ device was recorded for those subjects allocated to the
AcceledentÒ group over the trial duration (T0-T3). The AcceledentÒ device contains a timer which
stores usage data, which can be downloaded in Excel format and saved. Subjects in the
AcceledentÒ group were instructed to bring their vibration device with them at their T1, T2, and
T3 appointments, allegedly to check its function. Usage data was downloaded and saved to the
subject’s trial record. Average daily use was calculated between trial timepoints (T0-T1, T1-T2,
T2-T3) and for the overall trial duration (T0-T3).
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Some subjects did not use the AcceledentÒ device (average daily usage = 0 minutes) for multiple
days in a row leading up to the final trial timepoint (T3). A flaw of the AcceledentÒ timer is that
usage data is not recorded on the device when this situation occurs. Therefore, using the dates
between trial timepoints, days in which usage data was missing (because the subject did not use
the device) was calculated manually by recording the average daily usage as 0 minutes/day.

C. Statistics
The Mann-Whitney Test was used to assess differences between the AcceledentÒ and control
groups for all continuous variables: Periotest measurements, changes in Little’s Irregularity Index,
salivary biomarker concentrations, Visual Analog Scale scores, and Oral Health Quality of Life
scores with α=0.05.

Regression analysis was used to assess the effects of age, gender, and treatment group allocation
on the outcome variables of rate of alignment and the concentrations of salivary biomarkers of
bone remodeling. Significance was set at α=0.05.

Pearson’s correlation coefficient with α=0.001 was used to analyze possible correlations between
the salivary biomarker concentration, the change in the irregularity index, and the compliance with
the AcceledentÒ device.
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Chapter IV: Results

Forty patients were ultimately enrolled; of these, 20 (10 males and 10 females) were allocated to
the AcceledentÒ group and 20 (10 males and 10 females) were assigned to the control group. Trial
enrollment was initiated in June 2014 and was concluded in December 2017. Out of the 40 subjects
recruited, 3 subjects allocated to the control group were disqualified after enrollment. 1 female
subject decided to continue her orthodontic treatment in another clinic, 1 male patient failed to
present to his third appointment, and 1 female patient had an emergency medical procedure which
required the administration of an anti-inflammatory drug. All 40 enrolled subjects were included
in the final Intention to Treat (ITT) analysis, which is the recommended method in superiority
trials to avoid any bias [85]. See the CONSORT flow diagram in Figure 3 for the progress of
subjects through the phases of the trial.

The mean age of female subjects was 22.0 years and the mean age of male subjects was 18.7 years
at the start of treatment (T0). The mean age of subjects allocated to the AcceledentÒ and control
group at the beginning of the trial (T0) was 21.1 and 19.7 years old, respectively.

In regard to subjects’ compliance with the AcceledentÒ device, a wide range was observed. Based
on the data recorded by the device, usage ranged from 0% to 104%, with a mean compliance rate
of 53% (10.6 minutes/day) over the 3-month duration of the trial (T0-T3). When grouped by
gender, female subjects had an average compliance rate of 66% and male subjects had an average
compliance of 41%. Figure 4 shows the overall compliance over the trial duration (T0-T3) for
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each subject randomized into the AcceledentÒ group. When comparing compliance with the
AcceledentÒ device over the course of the trial, no overall trend could be appreciated; some
subjects stayed consistent with their compliance usage, others improved, while most subjects’
compliance decreased over the course of the trial (Figure 5).

The initial irregularity means for the control group was 9.23mm (SD: 3.30mm) while the
experimental group showed an average of 8.10mm (SD: 3.33mm), with no statistically significant
difference between the groups (p=0.234). Figure 6 shows the mean irregularity index at each trial
timepoint for both groups. There was no statistically significant difference found between the
experimental and control groups in terms of mean irregularity at each trial timepoint: T0, T1, T2,
T3 (P =0.234, 0.140, 0.125, 0.293, respectively). For the changes in irregularity over the trial
intervals, the data represented in Figure 7 shows that there were no significant differences in the
rate of alignment between groups during any trial interval: T0-T1, T1-T2, T2-T3, T0-T3 (p =
0.900, 0.643, 0.716, 0.713, respectively). Multivariate linear regression was completed to analyze
any potential associations between the initial irregularity, age, sex, and type of intervention on the
reduction of the irregularity index; however, no significant associations were found. Multivariate
linear regression was also completed to analyze potential associations between compliance with
the AcceledentÒ device and the change in Little’s Irregularity Index at different trial intervals;
however, no significant association was found. This data is presented in Table 3.

In terms of tooth mobility, as measured by the Periotest, there were no statistically significant
differences found between the AcceledentÒ and control groups for any teeth (lower right second
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premolar, lower right canine, lower right central incisor, lower left central incisor, lower left
canine, lower left second premolar) at any time points: T0 (p=0.829, 0.516, 0.607, 0.105, 0.787,
0.705, respectively), T1 (p=0.156, 0.779, 0.474, 0.866, 0.574, 0.888, respectively), T2 (p=0.090,
0.953, 0.698, 0.372, 0.781, 0.895, respectively), or T3 (p=0.703, 0.976, 0.038, 0.361, 0.637, 0.410,
respectively). See Figures 8, 9, 10, 11.

The Visual Analog Scores (VAS) illustrated by the pain diary are represented in Figures 12-14.
There were no significant differences in the level of pain intensity between AcceledentÒ and
control subjects on any day (Day 1-Day 7) following trial timepoints T0: (p =0.974, 0.091, 0.987,
0.508, 0.641, 0.507, 0.633, respectively) T1: (p=0.648, 0.351, 0.924, 0.632, 0.866, 0.614, 0.825,
respectively) and T2: (p= 0.910, 0.940, 0.509, 0.393, 0.674, 0.858, 0.919, respectively).

The evolution of Oral Health Quality of Life (OHQoL) during orthodontic treatment was assessed
using the Oral Health Impact Profile-14 (Figure 15). The OHQoL scores were not statistically
different between the AcceledentÒ and control subjects at any trial timepoints T0-T3 (p= 0.218,
0.574, 0.548, 0.552, respectively).

Temporal changes in the biomarker levels in the saliva were measured at each time points for all
17 biomarkers: IL-1β, IL-3, IL-6, IL-8, IL-11, IL-18, RANKL, TGFβ1, TNF-α, SOST, OPN, OPG,
MMP1, MMP8, MMP9, MMP13, and DKK1. The concentrations of all 17 biomarkers did not
differ significantly between the AcceledentÒ and control subjects at any trial timepoint: T0-T3.
For each biomarker, the following non-statistical significance differences were found between
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groups at T0, T1, T2, T3, respectively: IL-1β (p=0.705, 0.855, 0.629, 0.464), IL-3 (p=0.924, 0.712,
0.637, 0.902), IL-6 (p=0.607, 0.527, 0.770, 0.464), IL-8 (p=0.766, 0.249, 0.397, 0.976), IL-11
(p=0.516, 0.517, 0.464, 0.389), IL-18 (p=0.977, 0.965, 0.951, 0.847), RANKL (p=0.745, 0.491,
0.8772, 0.927), TGF-β1 (p=0.526, 0.765, 0.778, 0.695), TNF-α (p=0.323, 0.747, 0.619, 0.301),
SOST (0.665, 0.500, 0.203, 0.259), OPN (p=0.182, 0.213, 0.617, 0.939), OPG (p=0.574, 0.254,
0.658, 0.762), MMP1 (p=0.664, 0.661, 0.597, 0.290), MMP8 (p=0.570, 0.593, 0.953, 0.483),
MMP9 (p=0.579, 0.399, 0.907, 0.577), MMP13 (p=0.542, 0.612, 0.750, 0.939), and DKK-1
(p=0.848, 0.608, 0.965, 0.666). In addition, the ratio of RANKL/OPG concentration was analyzed
at T0, T1, T2, and T3 (p=0.892, 0.164, 0.977, 0.445). Figures 16, 17, 18, 19 show the data for IL1β, OPG, RANKL, and TNF-α, respectively, as examples. Furthermore, no significant correlations
were found between the rate of lower incisor alignment and the change of the concentration of
salivary biomarkers of bone remodeling during any trial intervals or over the trial duration (T0T3). See Tables 4, 5, 6, 7.

Chapter V: Discussion

At the present time, clinical research has centered around three principal techniques in an attempt
to increase the rate of tooth movement with the goal of decreasing the overall orthodontic treatment
time. These include pharmacological, surgical, and mechanical approaches which, in their own
specific way, attempt to modulate the underlying bone biology to increase the rate of tooth
movement. The motivation behind this varied research is the fact that fixed appliance treatment,
especially when the duration is prolonged, can result in consequences which are harmful to
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patients, such as white spot lesions [6] [7], caries [7], root resorption [8], and gingival
inflammation [9].

Regarding subjects’ compliance with the AcceledentÒ device, a wide range was observed in the
percentage of its use, with a mean compliance rate of 53% (10.6 minutes/day) over the 3-month
duration of the trial. This result is lower than the 67% compliance rate reported by Kau et al. [38]
and the 79% compliance reported by Miles et al. [44]. This could be due to the fact that we
discovered a flaw in the AcceledentÒ timer. If subjects did not use the device for multiple days
before the usage data was collected, these days were not recorded on the device. Therefore, in
these situations, the actual daily usage had to be calculated manually, by inputting 0 minutes/day
for these additional days. This flaw was not addressed in other studies, and could have possibly
been overlooked, leading to an over-estimate of patient compliance with the device [38] [44].
Some studies have investigated the effectiveness of the application of vibration in order to speed
up orthodontic treatment, in relation to alignment in patients with crowding, or space closure, in
patients undergoing an extraction treatment plan. However, up to the present day, no consensus
has been made. In our research, no statistically significant differences between groups were found
neither in the mean incisor irregularity at each trial timepoint nor in the changes in irregularity
over the 3 time intervals (T0-T1, T1-T2, T2-T3). These results are in agreement with other
randomized clinical trials by Miles et al. [40] [44], Woodhouse et al. [43], and DiBiase et al. [46]
which have all found in their respective studies, no increase in the rate of tooth movement (either
alignment or space closure) when vibration was used in conjunction with fixed appliances.
Contrarily, Pavlin et al. [39] found an average monthly rate of tooth movement of 1.16 mm/month
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when the AcceledentÒ appliance was used for 20 minutes daily, which they stated corresponded to
an increase of 48% in the rate of space closure compared to the control group. However, the
interpretation of these results should be viewed with caution, since their study was considered to
include low-quality evidence with a high risk of bias [42].

It is established that orthodontic tooth movement is a metabolic event featuring both bone
resorption on the compression side and bone apposition on the tension side of the tooth movement.
This alteration in the alveolar bone turnover is usually clinically associated with increased tooth
mobility [18] [53]. To our knowledge, this is the first study assessing the amount of tooth mobility
during orthodontic tooth movement and with supplemental vibration. In 2011, Liou et al. published
an article in which they assessed the post-operative changes in bone metabolism after orthognathic
surgery and the corresponding responses in the dento-alveolus, such as the changes in tooth
mobility [82]. Throughout the post-operative evaluation (4-month duration), one of the main
findings included an increase in tooth mobility between the first week after surgery and at the third
month follow-up appointment. However, in our research, no statistically significant differences in
the tooth mobility of lower premolars, canines, and central incisors were found between the control
group and the AcceledentÒ group who applied a vibrational force daily, at any of the 4 trial
timepoints (T0-T3). This makes clinical sense, as discussed previously, there was no difference in
the change of lower incisor alignment between the two groups; if the rate of tooth movement is
not significantly different, it would not be expected that tooth mobility would be significantly
affected.
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Previous studies have shown contradictory results of the pain levels in patients using a vibration
device. Lobre et al. found that the level of pain was significantly reduced by using the AcceledentÒ
device. They mentioned that using this device lowered the scores for overall pain and specifically
biting pain during the 4-month duration of their study [47]. Our findings showed contradictory
results to this study with no significant difference in the level of pain experienced by the subjects
using the AcceledentÒ device. Woodhouse et al. in 2015 determined that the only significant
predictor for mean pain was time. Their data also showed that the use of AcceledentÒ vibrational
device did not have any significant effect on the pain level or analgesic consumption during the
initial alignment phase [48]. In addition, our results are in agreement with Miles et al. who showed
no significant differences between groups in regard to pain [40] [44].

To follow, we did not find any significant differences in the Oral Heath and Quality of Life scores
between the subjects in the AcceledentÒ and control groups. However, we did notice a trend that
in both groups, scores increased at T1 and then decreased over the remainder of the trial. These
findings are in agreement with previous research which showed that some patients go through a
transitional phase of deterioration of the OHQoL during the first 4-6 weeks of orthodontic
treatment [51] [52]. This result could possibly be explained by the hypothesis that, following the
bonding appointment (T0), the patient can be self-conscious about the appearance of fixed
appliances, experience pain, ulceration or speech problems, which would increase the overall score
of the Oral Health Impact Profile (OHIP-14) questionnaire [51]. However, a prospective,
controlled trial by Johal et al. described Oral Health Quality of Life scores returning to baseline
values after the first 3 months of orthodontic treatment [51]. Our study appears to be the only one
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that compares patients’ quality of life with the use of a vibration device during orthodontic
treatment. Additional studies are needed to assess if there is any psychosocial impact from
vibration therapy that could improve the overall quality of life for orthodontic patients during fixed
appliance treatment.

It has been successfully demonstrated that pro-inflammatory cytokines have an important role
throughout the bone remodeling of the alveolus during orthodontic tooth movement by regulating
the inflammatory process of bone resorption. There has been a recent interest in this particular
research, both in rats and humans, in an attempt to elucidate the process of tooth movement. Rat
and human research focusing on TNF-α [68] [69], IL-1β [59] [60] [69] [70] [86], IL-6 [70], IL-8
[59] [70], MMP9 [59] [60] [62] [63], MMP8 [65] [66] [67], MMP13 [62] [64] [65], RANKL [29]
[59] [86], OPN [86], and TNF-β1 [86] has found increased concentrations of these biomarkers
after orthodontic force was applied. All of these pro-inflammatory biomarkers, as well as several
others noted for their role in bone remodeling [18], were selected for our Multiplex assay analysis.

On the clinical level, there has been only one study published by Leethanakul et al. in 2016. They
found that at 6 weeks after the start of vibration stimuli and orthodontic tooth movement there
were significant increases in the levels of IL-1β in the gingival crevicular fluid on the compression
side of the teeth which received vibration stimuli from an electric toothbrush. They also found an
increase in the rate of tooth movement (canine retraction) in the canines receiving vibratory stimuli
as compared with control canines. These clinically and biologically significant results differ from
those found in our study. In our study, when biomarker concentrations were analyzed throughout
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the trial duration between the control and AcceledentÒ groups, we found no statistically significant
differences. In addition, an important marker to illustrate the rate of bone turnover is the
RANKL/OPG ratio and multiple studies has clearly shown their rise during orthodontic tooth
movement [57] [58]; however, we did not find any differences in this ratio between groups over
the trial duration. When Pearson’s correlation analysis was completed, there were no significant
correlations between the rate of lower incisor alignment and the change in pro-inflammatory
biomarker concentrations for either AcceledentÒ or control groups. However, it is important to
acknowledge that this difference in the analysis of saliva versus gingival crevicular fluid could
affect biomarker detection, especially those which are expressed in lower concentrations in saliva.
Our aim with collecting and analyzing saliva was to allow for a future diagnostic tool that is noninvasive in nature, and for which sufficient quantities can be easily obtained for analysis.

Chapter VI: Conclusions

1. There was no difference in the expression of any of the analyzed biological markers of bone
remodeling between the AcceledentÒ and the control groups over the trial duration and no
association between the rate of alignment and compliance with the AcceledentÒ device.

2. There was no difference in the degree of tooth mobility in subjects undergoing combined
AcceledentÒ vibration-fixed appliance treatment and fixed appliance treatment alone.
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3. There was no difference in the rate of lower incisor alignment between subjects undergoing
combined AcceledentÒ vibration-fixed appliance treatment and fixed appliance treatment alone
over the 3-month trial interval and no correlation between the rate the lower incisor alignment
and the change in concentration of the analyzed biomarkers of bone remodeling during trial
intervals.

4. There was no difference in the level of pain experienced in and no difference in the quality of
life of subjects undergoing combined AcceledentÒ vibration-fixed appliance treatment
compared to fixed appliance treatment alone.

5. The average compliance usage of the AcceledentÒ device over the trial duration was 53%;
average compliance usage was 66% for female subjects and 41% for male subjects.
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FIGURES
Figure 1. Little’s Irregularity Index Measurements (Qualigio et al., 2012) [81]
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Figure 2. Pain Diary
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Figure 3. CONSORT Flow Diagram for Subject Participation

Enrollment
Assessed for eligibility (n= 45)

Excluded (n= 5)
¨ Not meeting inclusion criteria (n= 2)
¨ Declined to participate (n= 2)
¨ Other reasons (n= 1)

Randomized (n= 40)

Allocated to Experimental Group (n= 20)
¨ Received allocated intervention (n= 20)
¨ Did not receive allocated intervention (n= 0)

Allocation

Allocated to Control Group (n= 20)
¨ Received allocated intervention (n= 20)
¨ Did not receive allocated intervention (n= 0)

Follow-Up
Lost to follow-up (patient relocation) (n= 1)
Discontinued intervention (medication) (n= 1)
Failed appointment (n = 1)

Lost to follow-up (patient relocation) (n=0)
Discontinued intervention (medication) (n=0)
Failed appointment (n=0)

Analysis
Analyzed (n= 20)
¨ Excluded from analysis (n= 0)

Analyzed (n=20)
¨ Excluded from analysis (n= 0)
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Figure 4. Average Daily Usage of the AcceledentÒ Device over Trial Duration
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Figure 5. Average AcceledentÒ Usage over Trial Intervals
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Figure 6. Little’s Irregularity Index Between Groups at Trial Timepoints
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Figure 7. Change in Little’s Irregularity Index Between Groups over Trial Intervals
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Figure 8. Tooth Mobility in AcceledentÒ and Control Subjects at T0
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Figure 9. Tooth Mobility in AcceledentÒ and Control Subjects at T1
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Figure 10. Tooth Mobility in AcceledentÒ and Control Subjects at T2
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Figure 11. Tooth Mobility in AcceledentÒ and Control Subjects at T3
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Figure 12. Visual Analog Scale Scores between Groups for 1 Week after T0 Appointment
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Figure 13. Visual Analog Scale Scores between Groups for 1 Week after T1 Appointment
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Figure 14. Visual Analog Scale Scores between Groups for 1 Week after T2 Appointment
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Figure 15. Oral Health Quality of Life Scores over Trial Duration
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Figure 16. Concentration of IL-1β Between Groups over Trial Duration
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Figure 17. Concentration of OPG Between Groups over Trial Duration
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Figure 18. Concentration of RANKL Between Groups over Trial Duration
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Figure 19. Concentration of TNF-α Between Groups over Trial Duration
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TABLES
Table 1. Clinical Indications of Periotest Reading (Schulte, 1992)
Periotest Value (PTV)
-8.0 to +9.9

Clinical Indication
No movement distinguishable

+10.0 to +19.9

First distinguishable sign of mobility

+20.0 to +29.9

Crown deviates within 1mm of normal position

+30.0 to +50.0

Mobility easily noticeable

Table 2. Oral Health Quality of Life Questionnaire (OHIP-14) (Slade, 1997)
Dimension
Functional
Limitation

Question

Weight

Have you had trouble pronouncing any words because of problems with your teeth or
mouth?

0.51

Have you felt that your sense of taste has worsened because of problems with your teeth
or mouth?

0.49

Have you had painful aching in your mouth?

0.34

Have you found in uncomfortable to eat any foods because of problems with your teeth
or mouth?

0.66

Psychological
Discomfort

Have you been self-conscious because of your teeth or mouth?

0.45

Have you felt tense because of problems with your teeth or mouth?

0.55

Physical
Disability

Has your diet been unsatisfactory because of problems with your teeth or mouth?

0.52

Have you had to interrupt meals because of problems with your teeth or mouth?

0.48

Psychological
Disability

Have you found it difficult to relax because of problems with your teeth or mouth?

0.60

Have you been a bit embarrassed because of problems with your teeth or mouth?

0.40

Social
Disability

Have you been a bit irritable with other people because of problems with your teeth or
mouth?

0.62

Have you had difficulty doing your usual jobs because of problems with your teeth or
mouth?

0.38

Have you felt that life in general was less satisfying because of problems with your teeth
or mouth?

0.59

Have you been totally unable to function because of problems with your teeth or mouth?

0.41

Physical Pain

Handicap
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Table 3. Multivariate Linear Regression for Change in Irregularity and Average Daily
Compliance with AcceledentÒ Device
Dependent Variables
Irregularity T0-T1
Irregularity T1-T2

Independent Variable
Average Daily Compliance T0-T1
Average Daily Compliance T1-T2

B
-0.343
-0.508

95% Confidence Interval
-1.642 – 0.956
-1.949 – 0.932

p
0.595
0.479

Sig
NS
NS

Irregularity T2-T3
Irregularity T0-T3

Average Daily Compliance T2-T3
Average Daily Compliance T0-T3

-0.297
-1.149

-1.060 – 0.465
-3.464 – 1.166

0.434
0.321

NS
NS
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Table 4. Pearson’s Correlation between Change in Irregularity and Change in Biomarker
Concentration during T0-T1
Variables (T0-T1)
Irregularity and TNFα Concentration
Irregularity and TNFα Concentration

Group
AcceledentÒ
Control

R
0.174
0.088

p
0.463
0.721

Sig
NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL6 Concentration
IL6 Concentration
MMP9 Concentration
MMP9 Concentration

AcceledentÒ
Control
AcceledentÒ
Control

-0.082
-0161
-0.009
0.156

0.730
0.511
0.971
0.523

NS
NS
NS
NS

Irregularity and

IL3 Concentration

0.079

0.742

NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL3 Concentration
IL8 Concentration
IL8 Concentration
MMP1 Concentration
MMP1 Concentration
MMP8 Concentration
MMP8 Concentration
IL1β Concentration
IL1β Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

0.029
0.079
-0.024
0.075
0.136
-0.037
-0.048
0.012
0.028

0.906
0.739
0.924
0.753
0.578
0.878
0.845
0.96
0.908

NS
NS
NS
NS
NS
NS
NS
NS
NS

Irregularity and
Irregularity and
Irregularity and

DKK1 Concentration
DKK1 Concentration
MMP13 Concentration

0.105
0.016
0.297

0.659
0.947
0.203

NS
NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

MMP13 Concentration
SOST Concentration
SOST Concentration
RANKL Concentration
RANKL Concentration
OPN Concentration
OPN Concentration

AcceledentÒ
Control

0.149
0.246
0.137
0.019
0.052
0.074
0.189

0.541
0.296
0.575
0.938
0.834
0.756
0.439

NS
NS
NS
NS
NS
NS
NS

Irregularity and
Irregularity and

IL11 Concentration
IL11 Concentration

AcceledentÒ
Control

0.190
0.164

0.422
0.503

NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL18 Concentration
IL18 Concentration
OPG Concentration
OPG Concentration
TGFβ1 Concentration
TGFβ1 Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

0.336
0.118
-0.145
0.119
-0.037
0.011

0.147
0.632
0.543
0.627
0.877
0.963

NS
NS
NS
NS
NS
NS
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AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

Table 5. Pearson’s Correlation between Change in Irregularity and Change in Biomarker
Concentration during T1-T2
Variables (T1-T2)
Irregularity and TNFα Concentration
Irregularity and TNFα Concentration

Group
AcceledentÒ
Control

R
-0.118
-0.164

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL6 Concentration
IL6 Concentration
MMP9 Concentration
MMP9 Concentration
IL3 Concentration
IL3 Concentration
IL8 Concentration
IL8 Concentration
MMP1 Concentration
MMP1 Concentration
MMP8 Concentration
MMP8 Concentration
IL1β Concentration
IL1β Concentration
DKK1 Concentration
DKK1 Concentration
MMP13 Concentration
MMP13 Concentration
SOST Concentration
SOST Concentration
RANKL Concentration
RANKL Concentration
OPN Concentration
OPN Concentration
IL11 Concentration
IL11 Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL18 Concentration
IL18 Concentration
OPG Concentration
OPG Concentration
TGFβ1 Concentration
TGFβ1 Concentration
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p
0.620
0.515

Sig
NS
NS

-0.259

0.270

AcceledentÒ
Control

0.051
-0.496
-0.219
-0.268
-0.149
-0.481
-0.332
-0.545
0.108
-0.509
-0.037
-0.485
-0.311
-0.421
-0.11
-0.025
0.268
-0.126
0.216
-0.341
-0.291
-0.174
-0.043
-0.279
0.140

0.841
0.026
0.382
0.253
0.556
0.032
0.178
0.013
0.669
0.022
0.885
0.030
0.210
0.065
0.663
0.917
0.282
0.598
0.390
0.141
0.242
0.463
0.865
0.233
0.581

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

-0.505
0.096
-0.529
-0.339
-0.515
-0.387

0.023
0.704
0.016
0.169
0.020
0.113

NS
NS
NS
NS
NS
NS

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

Table 6. Pearson’s Correlation between Change in Irregularity and Change in Biomarker
Concentration during T2-T3
Variables (T2-T3)
Irregularity and TNFα Concentration
Irregularity and TNFα Concentration

Group
AcceledentÒ
Control

R
0.003
-0.231

p
0.991
0.390

Sig
NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL6 Concentration
IL6 Concentration
MMP9 Concentration
MMP9 Concentration
IL3 Concentration
IL3 Concentration
IL8 Concentration
IL8 Concentration
MMP1 Concentration
MMP1 Concentration
MMP8 Concentration
MMP8 Concentration
IL1β Concentration
IL1β Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

-0.023
-0.053
-0.447
-0.550
0.295
-0.122
-0.233
-0.354
0.074
-0.162
-0.115
-0.242
-0.147
-0.155

0.922
0.846
0.048
0.839
0.206
0.652
0.322
0.179
0.756
0.550
0.630
0.367
0.535
0.567

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

Irregularity and
Irregularity and
Irregularity and

DKK1 Concentration
DKK1 Concentration
MMP13 Concentration

0.239
-0.122
0.194

0.311
0.654
0.413

NS
NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

MMP13 Concentration
SOST Concentration
SOST Concentration
RANKL Concentration
RANKL Concentration
OPN Concentration
OPN Concentration
IL11 Concentration
IL11 Concentration
IL18 Concentration
IL18 Concentration
OPG Concentration
OPG Concentration
TGFβ1 Concentration
TGFβ1 Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

0.027
0.292
-0.426
0.234
-0.113
0.015
-0.268
-0.059
-0.162
0.190
-0.302
-0.377
-0.377
-0.298
0.194

0.921
0.212
0.100
0.321
0.678
0.950
0.315
0.803
0.549
0.422
0.256
0.146
0.150
0.202
0.472

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
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AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

Table 7. Pearson’s Correlation between Change in Irregularity and Change in Biomarker
Concentration during T0-T3
Variables (T0-T3)
Irregularity and TNFα Concentration
Irregularity and TNFα Concentration

Group
AcceledentÒ
Control

R
0.239
0.145

p
0.311
0.592

Sig
NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL6 Concentration
IL6 Concentration
MMP9 Concentration
MMP9 Concentration
IL3 Concentration
IL3 Concentration
IL8 Concentration
IL8 Concentration
MMP1 Concentration
MMP1 Concentration
MMP8 Concentration
MMP8 Concentration
IL1β Concentration
IL1β Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

0.112
0.306
-0.280
0.550
0.274
-0.095
-0.164
0.212
0.089
0.406
0.132
0.388
0.250
0.122

0.639
0.249
0.233
0.027
0.242
0.727
0.489
0.431
0.708
0.118
0.578
0.137
0.289
0.652

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

Irregularity and
Irregularity and
Irregularity and

DKK1 Concentration
DKK1 Concentration
MMP13 Concentration

0.132
-0.54
0.299

0.578
0.842
0.201

NS
NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

MMP13 Concentration
SOST Concentration
SOST Concentration
RANKL Concentration
RANKL Concentration
OPN Concentration
OPN Concentration
IL11 Concentration
IL11 Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

0.139
0.218
0.114
0.498
0.233
0.219
0.024
0.273
0.201

0.609
0.355
0.675
0.025
0.386
0.353
0.930
0.243
0.456

NS
NS
NS
NS
NS
NS
NS
NS
NS

Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and
Irregularity and

IL18 Concentration
IL18 Concentration
OPG Concentration
OPG Concentration
TGFβ1 Concentration
TGFβ1 Concentration

AcceledentÒ
Control
AcceledentÒ
Control
AcceledentÒ
Control

0.189
-0.101
-0.174
0.385
-0.360
0.086

0.424
0.709
0.462
0.141
0.119
0.751

NS
NS
NS
NS
NS
NS
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